[Treatment of occlusive cerebrovascular disease with a selective thromboxane A2 synthetase inhibitor].
D000179:Acrylates / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000097:blood / Q000188:drug therapy; D008297:Male; D008689:Methacrylates / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000179:Acrylates; D008689:Methacrylates; D013930:Thromboxane-A Synthase; C034364:ozagrel